City Therapeutics Starts Phase 1 Trial for CITY-RBP4
Biotechnology
Business Update
IPO:
Oct 16, 2026
Industry:
PHARMACEUTICAL PREPARATIONS
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
City Therapeutics Doses First Participant in Phase 1 Trial of CITY-RBP4 for Stargardt Disease
CAMBRIDGE, Mass., USA - City Therapeutics, Inc. (Nasdaq: CTY), a clinical-stage biotechnology company focused on RNA interference (RNAi) therapeutics, announced that the first participant has been dosed in the Phase 1 clinical trial of CITY-RBP4. The study aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of this investigational candidate in both healthy volunteers and patients with Stargardt disease.
... Read on — Members only
About CITY THERAPEUTICS, INC.
We are a clinical-stage biotechnology company developing the next generation of RNA interference (“RNAi”) therapeutics designed to silence the expression of disease-relevant proteins, with the aim of delivering meaningful and durable benefits for patients in need. We believe our deep RNAi expertise and City Platform capabilities uniquely position us to achieve our goal of developing potentially best-in-class therapeutics. Our vision is to lead the next generation of RNAi therapeutics, and our mission is to improve patients’ lives throug
